We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioFire Dx Initiates Clinical Study for the FilmArray™ Meningitis/Encephalitis Panel
News

BioFire Dx Initiates Clinical Study for the FilmArray™ Meningitis/Encephalitis Panel

BioFire Dx Initiates Clinical Study for the FilmArray™ Meningitis/Encephalitis Panel
News

BioFire Dx Initiates Clinical Study for the FilmArray™ Meningitis/Encephalitis Panel

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioFire Dx Initiates Clinical Study for the FilmArray™ Meningitis/Encephalitis Panel"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Infection of the meninges surrounding the brain and spinal cord (meningitis), or of the brain (encephalitis) can have high mortality and morbidity rates depending on the source of infection. Acute bacterial meningitis is a rare, but potentially fatal disease. Conversely, viral meningitis is more common, but typically mild and non-lethal. However, clinical diagnosis of the meningitis syndrome is difficult since their signs and symptoms are virtually indistinguishable. With a run time of about an hour, the comprehensive ME Panel requires only 200 µl of cerebrospinal fluid (CSF) to test simultaneously for 16 different bacterial, viral, and fungal pathogens known to cause community-acquired meningitis and encephalitis.

“The commencement of studies to evaluate our meningitis test is exciting since the FilmArray has the potential to make a profound impact on treating this fatal disease, where symptoms can appear suddenly and escalate quickly,” said Randy Rasmussen, bioMérieux Corporate VP Molecular biology and CEO of BioFire Diagnostics. “We look forward to introducing the ME Panel to clinical laboratories throughout the world.”

The clinical study is being conducted at numerous hospital-based clinical laboratories in the U.S. BioFire expects the FDA submission in 2015. The ME Panel will be the fourth clinical diagnostic test to run on the FilmArray System.

Additionally, BioFire will be exhibiting the FilmArray at booth 1257 during the 2014 American Association of Clinical Chemistry (AACC) annual meeting July 29-31 in Chicago, Ill.

Advertisement